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Abstract
In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast
cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly
metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires
activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined
several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by
IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-
231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response.
The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580
blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting
that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I
stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its
receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream
of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.
Introduction
The ability of breast cancer to metastasize to distant
organs leads to clinically incurable disease. The pheno-
types associated with metastatic breast cancer cells are
unregulated cell growth and survival, decreased cell–cell
adhesion, increased ability to degrade the extracellular
matrix, and increased cell motility. Cell motility changes
are associated with cytoskeletal reorganization and the
activation of multiple signaling pathways, which can be
induced by growth factors. Insulin-like growth factor-I
(IGF-I) has been shown to play important roles in
enhancement of breast cancer cell motility [1, 2]. Mul-
tiple signaling pathways are activated downstream of
the type I IGF receptor (IGF1R) and understanding
how these specific pathways contribute to cell motility
may be very important in the efforts to develop new
therapeutic strategies for breast cancer.
The family of Rho GTPases comprises a group of
signaling molecules that regulate a wide range of biolog-
ical processes in cancer, including reorganization of
cytoskeleton, cell-cycle control, apoptosis, tumorigenesis,
adhesion, invasion, and metastasis [3, 4]. Rho proteins
and their effectors are overexpressed in breast tumors and
expression levels positively correlate with the progression
of breast cancer [5–7]. RhoC GTPase is overexpressed in
90% of inflammatory breast cancer and positively cor-
relates with the tumor metastatic potential [8, 9]. In the
rat, Rho family GTPases were found to regulate mam-
mary epithelial cell growth and metastasis [10].
Rho-associated kinase (ROCK) is a major effector of
RhoA and RhoC. Upon activation by Rho, ROCK
inhibits myosin light chain (MLC) phosphatase and
results in an increase in MLC phosphorylation and,
consequently, increases myosin-based contractility [11].
ROCK also activates LIM-kinase (LIMK) and
subsequently phosphorylates cofilin and results in the
stabilization of actin filaments [12]. Both of these actions
result in enhanced cell motility. Yoshioka et al. reported
that the level and activity of endogenous LIMK1 is
increased in invasive breast and prostate cancer cell lines
and overexpression of LIMK1 in MCF-7 and in MDA-
MB-231 human breast cancer cell lines increased their
motility [13]. Taken together, these studies suggest that
Rho/ROCK signaling is involved in breast cancer
biology and warrant further investigation.
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In other cell system, Rho family GTPases have also
been reported to regulate p38-MAPK and JNK [14–16].
Erk and RhoA differentially regulate pseudopodia
growth and retraction during G protein coupled recep-
tor mediated chemotaxis [17]. ROCK signaling is in-
volved in the collapse of the vimentin intermediate
filament network, which may be an essential element in
chemokine-induced transendothelial migration [18, 19].
Rho GTPases are required in an oncogenic IGF1R-in-
duced NIH 3T3 cell transformation [20]. In Schwann
cells, IGF-I regulates cell motility by reorganization of
the actin cytoskeleton via the downstream activation of
a PI3K, Rac and cdc42 small GTPases, and FAK
pathway [21].
We have previously shown that IGF-I stimulates cell
adhesion and motility in a metastatic breast cancer cell
line, MDA-231BO, via a specific adaptor protein insulin
receptor substrate-2 (IRS-2). In this cell line, decreasing
levels of IRS-2 with an antisense construct will diminish
IGF-mediated motility [2]. We have also shown in this
cell system that IGF1R and integrin action are linked, as
disruption of integrin binding to its receptor influences
IGF-I signaling [22]. In this study, we further investi-
gated the signals downstream and adjacent to IRS-2
activation in MDA-231BO cells. We found that IGF-I
stimulated subcellular reorganization of IRS-2 and focal
adhesion kinase (FAK) while also inducing cytoskeletal
rearrangement. Along with these morphological chan-
ges, IGF-I stimulated RhoA activation and subse-
quently increased MLC phosphrylation. p38-MAPK
was also activated downstream of Rho/ROCK signal-
ing. Erk and PI-3K signaling pathway are also involved
in the IGF-I induced cell migration.
Materials and methods
Cells and reagents
MDA-231BO breast cancer cell line, a bone seeking
metastatic variant of MDA-MB-231 [23], was kindly
provided by Dr. Toshiyuki Yoneda (University of Texas
Health Science Center, San Antonio, TX). The culture
media and fibronectin were purchased from Life Tech-
nologies, Inc. (Rockville, MD). IGF-I was purchased
from Gro Pep (Adelaide, Australia). Rho assay kit and
IRS-2 antibody were purchased from Upstate Biotech-
nology (Waltham, MA). Phospho-MLC antibody (used
at 1:300 in immunoblotting) was kindly provided by
Dr. James M. Staddon (University College London,
UK) [24]. Horseradish peroxidase-conjugated RC-20
antiphosphotyrosine antibody was purchased from
Transduction Labs (Lexington, KY). a5 inhibitory and
b1 stimulatory integrin antibodies were purchased from
Chemicon (Temecula, CA). FAK and vimentin anti-
bodies were purchased from Santa Cruz Biotechnology,
Inc (Santa Cruz, CA). TRITC-labeled pholloidin, total
MLC antibody and all other chemicals were purchased
from Sigma (St. Louis, MO).
Rho activation assay
Total Rho (both GDP- and GTP-bound forms) assay
was performed according to manufacturer’s instruction
(Upstate). Levels of GTP-bound active-RhoA, RhoB,
RhoC and RhoG were measured by an activation assay
as previously described [25, 26]. Briefly, GST-rhotekin (a
gift from Dr. John Collard of the Netherlands Cancer
Institute) was prepared fresh from a 50 ml overnight
bacterial culture, stimulated for 2 h with 0.1 mM IPTG
to induce GST-protein production. GST-rhotekin was
bound to 50% slurry of glutathione-sephrose 4B
(Amersham, Uppsala, Sweden). MDA-231BO cells were
grown to 70% confluence, serum starved for 24 h in
IMEM zinc option (Gibco, Gaithersburg, MD), trypsi-
nized, washed and allowed to rest in suspension flasks
(Griener Bio-one, ISC Bioexpress, Kaysville, UT). Cells
were stimulated with 5 nM IGF-I and 10 · 106 cells/
time point were lysed with ice-cold GST-Fish buffer
(10% Glycerol, 50 mM Tris pH 7.4, 100 mM NaCl,
2 mM MgCl2, 1% NP-40) at 0, 1, 3, 10 and 30 min.
Protein lysates, 900 ll of 1 lg/ll, were precleared with
glutathione-sepharose 4B for 1 h at room temperature.
The cleared lysates were incubated with GST-rhotekin-
sephrose conjugate at 4 C for 30 min. The agarose
conjugate was washed three times in GST-Fish buffer,
collected by centrifugation, resuspended in Laemelli
buffer, separated by SDS-PAGE on an 8–20% Tris–HCl
gradient gel (BioRad, Hercules, CA), transferred to
nitrocellulose and probed with either RhoA, RhoB,
RhoC and RhoG antibodies (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Total (GTP- and GDP-bound)
RhoA, RhoB, RhoC and RhoG levels were measured at
each time point by Western blot analysis. Aliquots of
30 lg protein lysate were separated by SDS-PAGE,
transferred to nitrocellulose and probed with corre-
sponding antibodies (Santa Cruz Biotechnology). Each
analysis was performed in triplicate.
Cell motility assay
Cell motility was measured in a 10 well chamber as
previously described [2]. About 0.4 ml SFM with or
without IGF (5 nM) was placed in the bottom wells of
the chamber. A polycarbonate polyvinylpyrrolidone free
filter (12 lm pore size) was placed above this. Cells were
detached in PBS-EDTA and then were resuspended in
SFM. 0.3 ml cell suspension (5 · 105 cells/ml) was ad-
ded to the top well chamber above the filter. For the
inhibitor assays, cells were pretreated with inhibitors for
30 min at 37 C before they were added to the top wells.
The chamber was then incubated for 6 h at 37C. At the
end of the incubation, cells remaining on the topside of
the filter were scraped off with cotton swabs. The filter
was then removed from the chamber and the cells that
had migrated to the underside of the filter were fixed and
stained in HEMA3. The filter was mounted on a glass
microscope slide and cells were counted in 10 different
areas with the aid of a light microscope.
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Cell motility was also measured by gold particle
migration assay [27, 28]. Briefly, hot gold solution (22
part of H2O, 12 part of 36.5 mM sodium carbonate, 3.6
part of 14.5 mM gold chloride and 3.6 part of 0.1%
formaldehyde) was poured onto fibronectin coated glass
coverslips. Gold particles were allowed to precipitated
overnight at 4 C. Then the supernatant was discarded
and 2 · 104 cells were seeded on the gold particle coated
coverslips and allowed to adhere to the coverslip for
about 2 h before adding different treatments. Cells were
allowed to migrate for another 6 h and fixed with 3.5%
glutaraldehyde for 20 min and then the coverslips were
mounted with Permount. During the migration, cells
cleared up their pass, and the images were acquired
using a Spot 2 digital CCD on a Nikon E-1000 micro-
scope at [1x] and ImagePro Plus (Media Cybernetics
Inc., Silver Spring, MD) was used to quantify the
cleared areas.
Cell lysate preparation
Stimulation experiments were performed as previously
described. Briefly, cells were cultured in Dulbecco’s
Modification of Eagle’s Medium (DMEM, Cellgro,
Herndon, VA) with 10% fetal calf serum (Summit
Biotech, Fort Collins, CO) and 10 nM insulin until 70%
confluent, then washed twice with phosphate buffered
saline (PBS, Biofluids, Rockville, MD). Medium was
then changed to SFM for 24 h, then replaced with SFM
plus 5 nM IGF-I for 10 min. Cells were washed twice in
ice cold PBS and lysed with 500 ll per 10 cm plate with
TNESV buffer (50 mM- Tris-pH 7.4, 1% NP-40, 2 mM
EDTA, 100 mM NaCl, 10 mM sodium orthovanadate,
1 mM phenylmethylsulfonylfluoride, 20 lg/ml leupep-
tin, 20 lg/ml aprotinin). Protein concentration of the
cleared lysates was determined by the copper-bicinch-
oninic acid method with a Pierce Laboratory kit
(Rockford, IL).
Immunoprecipitation
All steps were performed on a platform rocker at 4 C.
Equal amounts of protein (500 lg) were first pre-cleared
with 25 ll of protein A agarose (Pierce, Rockford, IL)
for 30 min, then incubated with the FAK antibody
overnight at concentrations according to the manufac-
turer’s instructions. 25 ll of protein A agarose was then
added for 2 h, followed by three washes with TNESV
buffer. Beads were resuspended in 2· Laemmli loading
buffer with 30 mg/ml dithiothreitol, boiled and sepa-
rated by SDS-PAGE.
Immunoblotting
After SDS-PAGE proteins were transferred overnight to
nitrocellulose membranes (Bio Rad, Hercules, CA). All
blotting steps were carried out at room temperature with
gentle rocking. The membranes were blocked in 5%
non-fat dry milk in Tris-buffered saline -Tween 20
(TBST: 0.15 M CaCl2, 0.01 M Tris HCl- PH 7.4, 0.05%
Tween 20). For antiphosphotyrosine blotting with RC-
20, membranes were washed five times over 30 min with
TBST after blocking, incubated with a 1000:1 dilution in
TBST for 2 h, washed, then chemilumiescence was
performed as described below. The other blottings were
performed with 1 h incubation in primary antibody,
blots were then washed and incubated with a 2000:1
dilution of HRP linked anti-rabbit secondary antibody
in blocking buffer for 1 h, followed by further washing.
Enhanced chemiluminescence was performed according
to manufacturer’s instructions (Pierce, Rockford, IL).
Cell adhesion assay
Cell attachment was assayed in a 24 well tissue culture
plate. The wells were first coated with 0.2 ml of 10 lg/ml
fibronectin overnight at 4 C. Wells were then washed
twice with PBS. Serum-starved cells (1 · 106/ml) in
0.5 ml SFM plus/minus 5 nM IGF-I in the presence or
absence of 2 lM ROCK inhibitor Y-27632 were added
to the wells. After incubated for 45 min at 37 C, the
plate was rinsed three times with PBS to wash away the
non-attached cells. The attached cells were then fixed
onto the well with 20% methanol for 10 min at room
temperature. The fixed cells were stained with 0.5%
crystal violet in 20% methanol for 5 min and then rinsed
with water and air dried for 15 min. The crystal violet
contained cells were solubilized with 100 ll of 0.1 N
sodium citrate in 50% ethanol and transferred to 96 well
assay plate and read O.D. at 570 nm. The numbers of
attached cells were proportional to the number of O.D.
reading.
Confocal microscopy
To examine the expression and localization of IRS-2,
FAK and reorganization of F-actin and vimentin, we
performed confocal microscopy. MDA-231BO cells
were grown on fibronectin coated glass coverslips in the
presence of serum. After 24 h, cells were washed and
placed in SFM overnight. For immunofluorescent
visualization of IRS-2, FAK and vimentin, cells were
fixed with cold methanol for 20 min after treatment
(plus and minus 5 nM IGF) over several time points.
The fixed samples were then permeabilized with 0.1%
Triton X-100 in PBS for 20 min at room temperature.
After being washed three times with PBS and blocked
with 1% bovine serum albumin for 30 min, samples
were subjected to fluorescence staining by using unla-
beled IRS-2, FAK and vimentin primary antibodies and
FITC-labeled secondary antibodies for 1 h each at room
temperature. Cells were examined with a Bio-Rad
MRC-1024 confocal laser scanning microscope
(Hercules, CA) with a 60· objective lens under
oil immersion. F-actin was visualized by direct TRITC-
pholoidin binding to the fixed sample.
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Results
Alteration of subcellular localization IRS-2 and FAK
and reorganization of F-actin and vimentin during
IGF-mediated cell migration
We have previously shown that IGF-mediated cell
motility was diminished when IRS-2 levels were de-
creased by anti-sense RNA [2], while phosphorylation of
IRS-2 was only minimally affected. IGF1R and integrins
cooperate in this process [22] and it was possible that
IRS-2 molecules coordinated key signaling events in-
volved in cell motility. To determine if IGF-I exposure
influenced IRS-2 subcellular localization, we examined
cells by immunofluorescent microscopy. In the unstim-
ulated state, IRS-2 was primarily located in the cyto-
plasm (Figure 1, upper left panel), 60 min after IGF-I
exposure IRS-2 could be found at the cell’s leading edge.
This result was also demonstrated in MCF-7 ATCC
cells and it was specific to IGF-I treatment [29].
During cell migration, constant morphological
changes occur. The regulation of morphological changes
in eukaryotic cells is a complex process involving major
reorganization of cytoskeleton components including
actin microfilaments, microtubules and intermediate fil-
aments. It has been reported that Rho activation is
involved in the collapse of the vimentin intermediate
filament network and in the polymerization of actin fibers
[19]. Therefore, we investigated if F-actin and vimentin
went through reorganization during IGF-I mediated cell
migration. As shown in Figure 1 (upper right panel), in
unstimulated cells actin staining was diffusely detected in
the entire cell body. After IGF-I treatment, F-actin was
bundled along the cell border. In contrast to actin, vi-
mentin was bundled before IGF-I treatment and became
less organized during IGF-I mediated cell migration
(Figure 1, lower right panel). Thus, IGF-I treatment
resulted in morphologic reorganization of the cytoskel-
eton required for the initiation of cell migration.
IGF-I has been shown to either positively or neg-
atively modulate focal adhesion proteins involved in
integrin signaling such as FAK, Cas, and paxillin. We
examined the ability of IGF-I to stimulate FAK acti-
vation by immunoprecipitation followed by anti-phos-
pho-tyrosine blotting (Figure 2). In cells attached to
substrate, IGF-I treatment did not increase FAK
phosphorylation. However, FAK localization after
IGF-I treatment, was substantially altered (Figure 1,
lower left panel). As cells start to spread and migrate
after IGF-I exposure, FAK gradually disappeared
from focal adhesion sites. Further, cells in suspension
have very little FAK activation and attachment to
fibronectin will stimulate its phosphorylation (Fig-
ure 2). Inhibitory a5 integrin antibody blocked this
activation but stimulatory b1 integrin antibody did not
(Figure 2). These results suggest that FAK phosphor-
ylation is mainly regulated by integrin signaling while
subcellular localization of FAK was influenced by
IGF-I treatment. Thus, IGF-I may play an important
role in regulating focal adhesion contacts by coordi-
nating FAK localization without activating its kinase
activity.
IGF-I stimulated Rho A activation in MDA-231BO
cells in suspension
The formation and remodeling of focal contacts and the
cytoskeletal changes during cell movement are dynamic
processes, which are under the regulation of protein
tyrosine kinases and the Rho family of small GTPases.
To determine if IGF-I stimulated Rho activation, we
measured the GTP-bound (activated) and total Rho in
MDA-231BO cells. As shown in Figure 3a, IGF-I rap-
idly stimulated Rho activation 2-fold within 3 min in
Figure 1. IRS-2 and FAK cellular locations were altered by IGF-I during cytoskeletal reorganization. Metastatic variant MDA-231 BO cells were
grown on glass coverslips coated with fibronectin. Cells were incubated in media containing fetal bovine serum overnight, then cells were starved
with SFM for 24 h. Cells were then treated with or without 5 nM IGF-I for 1 h and fixed and stained for IRS-2, FAK, F-actin and vimentin.
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cells in suspension. In order to determine the species of
Rho activated we further examined RhoA, RhoB, RhoC
and RhoG activation by immunoprecipitation with
specific antibodies. As shown in Figure 3b, RhoA was
activated by IGF-I treatment within 1 min. RhoB acti-
vation was decreased by IGF-I treatment, while RhoC
and RhoG were unchanged (data not shown). IGF-I
treatment had minimal effect on Cdc42 activation while
GTP-bound Rac1 was slightly increased. We also failed
to detect IGF-I effect on RhoA activation in attached
MDA-231BO cells (data not shown), suggesting the
IGF-I stimulatory effect on Rho occurred in cells
detached from extracellular matrix.
Rho-kinase (ROCK) inhibitor Y-27632 effectively
inhibited IGF-I mediated cell migration in MDA-231BO
cells, but not cell adhesion
ROCK is one of the best characterized downstream Rho
effectors. Upon its activation, ROCK inhibits myosin
light chain phosphatase to enhance phosphorylation of
MLC, which has essential role in cell contractility.
Several compounds have been developed to block
ROCK, including Y-27632 [30]. To determine if ROCK
acting downstream of RhoA had a role in IGF-mediated
motility, we treated MDA-231BO cells with Y-27632
(0.2–200 lM) prior to IGF-I exposure. As shown in
Figure 4a, low concentrations of Y-27632 (less than
2 lM) effectively blocked IGF-I stimulated cell migra-
tion. Higher concentrations (>2 lM) blocked both
basal and IGF-stimulated cell migration. To examine
MLC phosphorylation in response to IGF-I, we treated
suspension cells with IGF-I in the presence or absence of
2 lM Y-27632. Figure 4b shows that IGF-I stimulated
MLC phosphorylation while Y-27632 effectively
blocked this activation.
In Boyden chamber assays, cell adhesion is a pre-
requisite of cell migration. We have previously shown
that IGF-I enhances both motility and adhesion in
MDA-231BO cells [2]. At concentrations shown to in-
hibit migration, Y-27632 had no effect on IGF-I stim-
ulated adhesion to fibronectin (Figure 4c). To confirm
that ROCK affected migration of cells already attached
to the substrate, we used a gold particle migration assay,
which allows cells to adhere prior to the measurement of
motility. As shown in Figure 4d, 2 lM Y-27632 inhib-
ited IGF-I stimulated motility at a level similar to that
observed in the Boyden chamber assay (Figure 4a).
Figure 3. IGF-I stimulated Rho A activation in MDA-231BO breast cancer cells (a) MDA-231BO cells in suspension were examined for total
Rho activation after treatment with 5 nM IGF-I for 3,10 and 30 min by using the Rho assay kit as described in Materials and Methods.
Treatment with lysophosphatidic acid (LPA) for 3 min was used as a positive control. The graph demonstrates the density of the bands and
quantified as the ratio of activated Rho/total Rho (as internal control). The experiment was repeated three times; a representative example is
shown. (b) MDA-231BO cells in suspension were examined for RhoA, B, and Rac1 and cdc42 activation (GTP bound) after treatment with 5 nM
IGF-I for 3, 10 and 30 min as described in the methods. Total protein immunoblots blots for corresponding small GTPases (IB) were used as
loading control. The experiment was repeated three times; a representative example is shown.
Figure 2. IGF-I did not affect FAK tyrosine phosphorylation. MDA-
231BO cells were incubated for 30 min in the presence of a5 integrin
inhibitory antibody, b1 integrin stimulatory antibody or no additional
antibody. After pre-incubation, cells were treated with or without
5 nM IGF-I and allowed to attach to the fibronectin coated plate for
30 min. Another set of cells was in suspension and treated with and
without IGF for 30 min. Cell lysates were immunoprecipitated with
FAK antibody followed by anti-phospho- tyrosine blotting. Then the
same blots were stripped and reblotted with FAK antibody. The
experiment was repeated three times; a representative example is
shown.
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Thus, IGF1R activation of ROCK stimulates motility
without influencing cell adhesion.
MAPK, PI-3K, and p38 activities are also required
for IGF-I stimulated MDA-231BO cell migration
We and others have shown that IGF-I stimulates both
MAPK and PI-3K in MCF-7 breast cancer cells to
enhance growth [31, 32]. To determine if these pathways
are also involved in IGF-mediated cell migration, we
pre-treated MDA-231BO cells with either PD98059
(MEK inhibitor) or wortmannin (PI3K inhibitor) prior
to IGF-I exposure. We have previously shown that these
chemicals inhibit IGF-stimulated cell proliferation [31].
Figure 5 shows that both compounds blocked the IGF-I
stimulated cell migration. Immunoblotting results show
that MDA-231BO cells have constitutively activated
MAPK. PD98059 did not completely block the MAPK
phosphorylation even at very high concentration
(Figure 6a). In contrast, 75 nM wortmannin inhibited
IGF-I activation of Akt, a downstream target of PI3K
(Figure 6b). These results suggested that MAPK and PI-
3K signaling pathways are required for IGF-I mediated
cell migration. However, MAPK was not stimulated by
IGF-I, suggesting that it was not a direct effector of
IGF-I stimulated cell migration. In addition, since PI3K
is activated by IGF-I in non-migrating cells this path-
way may have a role in both mediating mitosis and
motility.
Since p38 has been reported to be activated by small
GTPases, we next examined if IGF-I could activate p38
phosphorylation. As shown in Figure 7a, IGF-I stimu-
lated p38 phosphorylation in a time course similar to
Figure 4. ROCK inhibitor Y-27632 blocked MLC phosphorylation and motility in MDA-231BO cells. (a) MDA-231BO cells were incubated in
increasing concentrations (0.2–200 lM) of ROCK inhibitor Y-27632. Cell motility was examined in both basal and 5 nM IGF-I containing media
using the modified Boyden chamber assay. Results are shown as percentage basal migration (without IGF-I and Y-27632). (b) Metastatic variant
MDA-231BO cells in suspension were examined for levels of phospho-MLC and total MLC by immunoblotting after treatment with or without
5 nM IGF-I for 10 min with or without pretreatment of Y-27632 (2 lM). Figure labeling: S-SFM; I-IGF; Y-Y27632. (c) MDA-231BO cell
adhesion to fibronectin was examined in the presence and absence of 5 nM IGF-I and Y-27632. The results were shown as O.D. reading at
570 nm, which was proportional to the adherent cell number. (d) MDA-231BO cell motility was examined in the presence and absence of IGF-I
(5 nM) and Y-27632 (2 lM) using the gold particle migration assay. The results are shown as percentage by using basal migration (without IGF-I
and Y-27632) as a 100% control.
















Figure 5. PI-3K and MAPK inhibitors blocked IGF-I stimulated
MDA-231BO cell motility. MDA-231BO cells were treated with
vehicle (DMSO), 25 lM PD98059 (PD), 250 nM wortmannin (WT) or
no pre-treatment (CTRL) for 30 min prior to IGF-I treatment. Results
are shown as percent of control (serum free media).
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RhoA activation (Figure 3a). ROCK inhibitor Y-27632
could partially block both basal and IGF-I stimulated
p38 phosphorylation (Figure 7b). SB203580 specifically
inhibits p38 at low concentrations (4–20 lM) while
higher concentrations also inhibit other kinases such as
LCK, PKBa, GSK3b, c-Raf and JNK2b1. In these cells,
low concentrations of SB203580 inhibited IGF-I effects
while concentrations greater than 50 lM also blocked
basal cell migration (Figure 7c). Since both Y-27632 and
SB203580 inhibited IGF-I stimulated motility and p38
activation; these data suggest that p38 may be down-
stream of RhoA/ROCK.
Discussion
Cell migration is a dynamic process requiring the inte-
gration of multiple signaling pathways. Moving cells are
constantly exposed to mechanical and chemical envi-
ronmental cues [33]. Engagement of integrin receptors
with their extracellular ligands leads to the formation of
focal adhesion contacts, which links the ECM with the
intracellular actin cytoskeleton. Thus, mechanical forces
generated by the cell’s own actin–myosin contractile
machinery are activated by specific ECM proteins found
in the extracellular environment. At same time, cells are
receiving additional environmental signal, from mole-
cules such as growth factors, via their own cognate cell
surface receptors.
IGF-I initiates its biological effects by interacting
with IGF1R, which then recruits and phosphorylates
specific adaptor proteins including the IRS molecules.
We have previously shown IRS-2 is involved in IGF-I
mediated cell migration in MDA-231 breast cancer cells
[2], but the exact function for IRS-2 in this process is not
well defined. In this study, we further investigated IRS-2
subcellular localization after IGF-I exposure. We found
that IGF-I causes IRS-2 to concentrate at the cell
leading edge, which supports its role in sensing the
environmental cues and directing cell movement.
FAK is a major kinase located at focal adhesion
contacts and initiates the actin–myosin mechanical
force upon appropriate integrin ligation. We have
found that MDA-231BO cells have very low FAK
activity (phosphorylation) in suspension. By allowing
cellular attachment to attach to fibronectin coated plate
Figure 6. Effect of PD98059 and wortmannin on IGF-I mediated
MAPK and PI-3K signaling. (a) MAPK activation was measured by
phosphospecific antibodies (top panel) in the presence of increasing
concentrations of PD98059. Phospho-MAPK was detected in
unstimulated cells and IGF-I did not increase levels PD98059 inhibited
MAPK signaling in samples treated with or without IGF-I. (b) AKT
activation was measured by phosphospecific antibodies. 5 nM IGF-I
stimulated AKT phosphorylation and this activation was inhibited by
250 nM wortmanin.
Figure 7. p38 inhibition inhibited IGF-I stimulated cell motility (a) Phosphospecific antibodies were used to measure activated p38. Cells were
treated with 5 nM IGF-I from 0–30 min. p38 was activated by IGF-I in a time course similar to that of RhoA. (b) ROCK inhibitor Y-27632
(2 lM) partially inhibited p38 signaling in attached MDA-231BO cells with and without IGF-I treatment. (c) SB203580 (4–200 lM) inhibited
both basal and IGF-I stimulated cell migration in a dose-dependent manner in MDA-231BO cells.
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for 10 min, FAK is highly activated and IGF-I has no
effect on FAK activity either in suspended or attached
cells. In accordance with the report that IGF-I induces
dephosphorylation of FAK in MCF-7 breast cancer
cells [34], we found that FAK gradually disappeared
from focal adhesion sites after IGF-I treatment. These
results suggest that in MDA-231BO breast cancer cells,
FAK activation is mainly regulated by integrin ligation
while IGF-I downregulates FAK activity by diminish-
ing its presence at the focal adhesion contacts. Recent
report suggests that Src family kinases are essential for
the phosphorylation-dependent exclusion of FAK from
focal adhesions [35]. Thus, tyrosine kinase activity ini-
tiated by IGF-I may enhance cell movement by
diminishing focal adhesions. Recently, Lynch et al.
have shown that IGF-I decreases adhesion strength of
MCF-7 cells transfected with IGF1R [36]. These
authors find that the IGF-mediate effects of adhesion
strength are independent of ROCK activation, but are
dependent on IGF1R signaling to PI-3K. While these
cells express supraphysiologic levels of IGF1R, the
results support the idea that complex signaling initiated
by this receptor can mediate several aspects of breast
cancer cell motility.
The mechanical properties of the cell are largely
regulated by cytoskeletal architecture of microfilaments,
intermediate filaments (IF), and microtubules. Vimentin
belongs to the IF network and little is known about its
function in migrating cells. Recently, it has been reported
that the rigidity of circulating lymphocytes is primarily
conferred by vimentin and their regulated collapse is
likely to be an essential element in chemokine-induced
transendothelial migration [18]. Overexpression of
RhoA or growth factor treatment is associated with
disassembly of vimentin IFs in fibroblasts and rat me-
sangial cells [19, 37]. In this study, we also found that
before IGF-I treatment, MDA-231BO cells contain a
perinuclear ring of vimentin. During IGF-mediated cell
migration, the vimentin ring loosened and became dis-
sembled. The collapse of vimentin network may be nec-
essary to achieve the increased cell deformability
required for IGF-I mediated cell migration. It has been
reported that vimentin phosphorylated by ROCK also
loses its ability to form filaments in vitro [38].
Rho family GTPases control cell adhesion and
motility through reorganization of the actin cytoskele-
ton and regulation of actomyosin contractility [39]. In
this study, we failed to detect Rho activation in attached
cells after IGF-I treatment for as long as 30 min.
However, with cells in suspension, IGF-I rapidly stim-
ulated RhoA activation within 1 min. GTP-bound
RhoB was decreased after IGF-I treatment. IGF-I did
not change levels of GTP-bound RhoC, RhoG or cdc42.
Our findings suggest that IGF-I activation of RhoA may
have a very important role in detached cells, as would be
found in circulating tumor cells. It is clear that a sig-
nificant number of ‘early stage’ breast cancer patients
have circulating tumor cells [40]. While the presence of
these cells is a poor prognostic factor, it is also clear that
many women with circulating tumor cells do not suffer
clinical disease recurrence. It is possible that additional
growth factor-mediated signaling events are necessary
for circulating tumor cells to display their full metastatic
potential.
In further study of RhoA activation by IGF-I, we
found that ROCK inhibitor Y-27632 effectively inhib-
ited IGF-I mediated cell migration in MDA-231BO
cells. The fact that IGF-I stimulated cell adhesion was
not affected by ROCK inhibitor indicates other signal-
ing pathway, other than Rho, may be required for
IGF-stimulated adhesion. During migration, cell body
contraction depends on phosphorylation of actomyosin.
ROCK inhibits MLC phosphatase allowing enhanced
activity of MLC. We show that MLC phosphorylation
is induced by IGF-I and, as expected, inhibition of
ROCK inhibits IGF-mediated cell motility. Rho-
ROCK-MLC signaling pathway is involved in IGF-I
stimulated cell motility in metastatic breast cancer cells.
p38-MAPK has been reported to be activated either
by cdc42/Rac/PAK/MKK3/6 mediated pathway [16, 41]
or by Rho/ROCK signaling [14]. In MDA-231BO cells,
IGF-I did not affect Rac and cdc42 activity. On the
other hand, IGF-I stimulated p38 phosphorylation in a
manner similar to RhoA activation. Furthermore,
ROCK inhibitor Y-27632 diminished both basal and
IGF-I stimulated p38 activity. These data suggest that
p38 is downstream of RhoA/ROCK in MDA-231BO
breast cancer cells.
Erk and PI-3K signaling pathways are well studied
and play important roles in almost every aspect of cancer
cell biology. We have also shown previously that
both pathways are required in IGF-mediated growth in
MCF-7 cells [31]. In MDA-231BO cells, monolayer
growth is not stimulated by IGF-I (data not shown).
MDA-231BO cells have constitutively activated Erk1 and
Erk2 and no further stimulation was evident after IGF-I
treatment. In contrast, Akt was activated by IGF-I in
these cells. Inhibition of Erk and PI-3K inhibited IGF-I
mediated cell migration, suggesting both pathways are
necessary for this phenotype. Activation of MAPK ap-
pears to be a required pathway for motility but does not
appear to be downstream of IGF action in these cells.
In summary, IGF-I mediated MDA-231BO breast
cancer cell migration requires coordination of multiple
signaling pathways. Some of the pathways are inde-
pendent of IGF-I action, such as MAPK, but oth-
ers (RhoA/ROCK/MLC) appear directly activated by
IGF-I. In addition, coordinated signaling through
integrin receptors is also necessary for IGF-I stimulated
motility. Our data suggest that the metastatic phenotype
is potentially vulnerable to inhibition of IGF signaling.
Moreover, optimal inhibition of the metastatic pheno-
type may require blockade of several molecules, either in
series or in parallel. Since many of the appropriate
inhibitors are now being tested in clinical trial, the
complexity of the contributions of multiple signaling
components to metastasis needs to be considered to
design the most effective cancer therapies.
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